OptimizeRx Corp. (NASDAQ:OPRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of OptimizeRx Corp. (NASDAQ:OPRX) have been assigned an average rating of “Moderate Buy” from the nine analysts that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $17.5714.

A number of brokerages recently weighed in on OPRX. Stifel Nicolaus lowered their price target on shares of OptimizeRx from $21.00 to $17.00 and set a “buy” rating for the company in a report on Friday, March 6th. Lake Street Capital reduced their price objective on OptimizeRx from $24.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, March 6th. Zacks Research upgraded OptimizeRx from a “hold” rating to a “strong-buy” rating in a research report on Friday, March 13th. Stephens lowered their target price on OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating for the company in a research note on Friday, March 6th. Finally, Roth Mkm dropped their target price on OptimizeRx from $32.00 to $18.00 and set a “buy” rating for the company in a research report on Friday, March 6th.

Institutional Investors Weigh In On OptimizeRx

Institutional investors and hedge funds have recently modified their holdings of the business. Quantbot Technologies LP acquired a new position in OptimizeRx in the second quarter valued at approximately $44,000. BNP Paribas Financial Markets raised its position in shares of OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after acquiring an additional 2,215 shares during the last quarter. State of Alaska Department of Revenue acquired a new position in shares of OptimizeRx in the 4th quarter valued at $62,000. USA Financial Formulas acquired a new position in shares of OptimizeRx in the 3rd quarter valued at $131,000. Finally, ExodusPoint Capital Management LP bought a new position in shares of OptimizeRx in the 4th quarter worth $150,000. 76.47% of the stock is owned by institutional investors.

OptimizeRx Stock Performance

Shares of NASDAQ:OPRX opened at $6.60 on Friday. The business has a fifty day moving average of $8.62 and a 200-day moving average of $13.57. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.04 and a current ratio of 3.04. OptimizeRx has a twelve month low of $5.54 and a twelve month high of $22.25. The firm has a market cap of $123.82 million, a PE ratio of 25.39 and a beta of 1.20.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings results on Saturday, January 31st. The company reported $0.51 earnings per share (EPS) for the quarter. OptimizeRx had a net margin of 4.69% and a return on equity of 10.61%. On average, equities research analysts predict that OptimizeRx will post -0.33 EPS for the current fiscal year.

OptimizeRx declared that its board has initiated a share repurchase plan on Thursday, March 5th that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.